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The Food and Drug Administration (hereinafter, FDA) regulates food, drugs,
and cosmetics in order to ensure that these products are safe and truthfully
labelled. As part of its responsibilities under the Federal Food, Drug, and Cos-
metic Act (hereinafter, Act), the FDA monitors the manufacturing practices
of companies involved in the production of food, drugs, and medical devices.
The manufacturing practices used by these companies must comply with cer-
tain standards, identied in the Act as current good manufacturing practices
(hereinafter, CGMP). If a company's practices do not conform with CGMPs,
the nished products are considered adulterated, even if the products are tech-
nically perfect. The purpose of CGMPs is to assure the safety and ecacy of
the nished products.
CGMP represents a process-oriented regulation{a regulation which
focuses on the technology and/or practices used in production, rather than on
the output. By managing the process, the regulatory agency can also control
the quality and impacts of the completed product. This paper reviews the basic
aspects of the CGMP requirement and considers whether government agencies
should be involved in regulating the process as well as the nal product. In
addressing the process-product distinction, the paper compares the CGMP reg-
ulations to a similar process-oriented regulation found in the Clean Air Act{the
requirement that certain permitted facilities use the best available control tech-
1nology. Basic Features of CGMP
The requirement that manufacturers comply with current good
manufacturing practices originates in the Federal Food, Drug and Cosmetic
Act. The Act specically mentions conformity with CGMP only in relation to
medical drugs and devices.1 Section
501(a)(2)(B) of the Act requires the methods, facilities, and con-
trols used in the manufacture, processing, packing and holding of a drug product
to conform to current good manufacturing practice in order to assure that the
drug meets the safety requirements of the Act and that the drug has the identity,
strength, quality, and purity which it purports to possess. Section 520(f)(1)(A)
authorizes the Secretary of Health, Education and Welfare to prescribe regu-
lations requiring conformity with CGMP in the manufacture, pre-production
design validation, packing, storage, and installation of medical devices.2 The
Act does not specically mention CGMP in relation to the production of food.
In order to promulgate CGMP regulations for food production, the FDA relies
upon statutory authority which deems food to be adulterated if it consists of
any lthy, putrid, or decomposed substance or if it has been prepared, packed,
or held under insanitary conditions where it may have become contaminated
with lth.3 The regulations establish the practices a food manufacturer should
1Federal Food, Drug, and Cosmetic Act 501(a)(2)(B), 21 U.S.C. 351 (1988 & Supp.
V) (requiring compliance with CGMP in the manufacture of drugs); Federal Food, Drug,
and Cosmetic Act 520(f)(1)(A), 21 U.S.C. 360(j)(t) (1988 & Supp. V) (permitting the
promulgation of regulations for COMP related to the manufacture of medical devices).
2Section 501(a)(2)(B) of the Act does not provide the Secretary with the authority to
promulgate CGMP regulations relating to the manufacture of drugs. The Secretary derives
the authority from Section 701 of the Act, which gives the Secretary the authority to prescribe
regulations for the ecient enforcement of the Act. Federal Food, Drug, and Cosmetic Act
701(a), 21 U.S.C. 371(a) (1988 & Supp. V).
3Federal Food, Drug, and Cosmetic Act 402(a)(3), (4), 21 U.S.C. 342 (1988 & Supp. V).
2follow in order to avoid violating this section of the Act.4
By regulating the manufacturing practices of food and drug pro-
ducers, the FDA places emphasis on the process, as well as the nal product.
As explained in the statute and the corresponding regulations, the purpose of
requiring conformity with CGMPs is to assure the safety and ecacy of the
product.5 With drug products, CGMPs are also designed to ensure the drug
has the identity and strength, and meets the quality and purity characteristics,
which it purports to possess. Following the CGMP regulations does not guaran-
tee that a properly manufactured product will not be adulterated; [d]efects can
creep into a nished product in spite of the most careful adherence to any kind
of GMPs. 6 Likewise, approval of the selected manufacturing standards and
procedures outlined in a new drug application (NDA) or an abbreviated new
drug application (ANDA) does not shield a company from FDA action if the
process generates failures to comply with CGMP regulations. In United States
v. Barr Laboratories, inc., the court determined that an ANDA guides a prod-
uct's manufacture and release, but does not supersede the overarching CGMP
requirements.7 However, CGMPs can guide manufacturers to the establish-
ment of reasonable practices and procedures that are capable of reproduction
and which reduce the possibility of a process which will lead to or allow the
production of an adulterated product. 8The CGMP requirement allows FDA to
4Stephen H. McNamara, Preparing for Cosmetic GMP{A Legal Perspeaive, 35 Food
Drug Cosm. L.J. 651, 654-655 (1980).
5E.g., 21 U.S.C.  351, 360(j) (1988 & Supp. V); 21 C.F.R. 210.1(a) (1994).
6Patrick V. Gibbons, Legal Implications of GMP Regulations. 31 Food Drug Cosm. L.J.
473, 475 (1976).
7Barr Laboroiories, 812 F.Supp. at 465.
8Christopher L. Hagenbush, How the FDA and Indust,y Use Guidelines in Dening and
3monitor operations and correct faulty manufacturing processes before defective
products are completed.9
FDA must also monitor the manufacturing process to ensure that
a company does not violate the legal denition of adulterated. Under Section
501(a)(2)(B) of the Act, a pharmaceutically-perfect drug is considered to be
adulterated if the manufacturer did not comply with the CGMP regulations
during production.10 By including the requirement of compliance with CGMP
in the statute and by promulgating CGMP regulations to guide manufacturers,
Congress and the FDA underscore the important connection between the quality
of the process and the quality of the nished product.
Regulations and Guidelines
The CGMP requirement established in the Federal Food, Drug,
and Cosmetic Act provides only a general standard against which rms can
measure their manufacturing processes. Several courts, however, have found
that the drug GMP requirement is not unconstitutionally vague. According to
the courts, CGMP is a term of art directed at a particular group, who can be
expected to know the actions and procedures necessary to comply with the stan-
dard.11 In addition, FDA provides more specic guidance through regulations
Interpreting Statutory Requirements, 38 Food Drug and Cosm. L.J. 177, 181 (1983) (emphasis
added).
9Seymour B. Jeries, Current Good Manufacturing Practices Compliance{A Review of the
Problems and an Approach to Their Management, 23 Food Drug Cosm. L.J. 580 (1968).
10E.g., United States v. Barr Laboratories, Inc., 812 F.Supp. 458, 486 (D.N.J. 1993) (citing
United States v. Lit. Drug Co., 333 F.Supp. 990, 998 (D.N.J. 1971)) (indicating the relevant
inquiry in determining whether a drug is adulterated focuses on the legal denition, not on
the pharmaceutical perfection of the drug); Gibbons, supra note 6, at 475.
11McNamara, supra note 4. at 653 (citing United States v. An Article of Drug.. White
Quadrisect. 484 F.2d 748 (CA-7, 1973), United States v. Kendall Co., 324 F.Supp. 628 (D.C.
Mass. 1971), United States v. Bel-Mar Laboratories, Inc., 284 F.Supp. 875 (D.C. E.D. N.Y.
1968)).
4and guidelines, assisting companies in determining the type of manufacturing
practices which qualify as current and good.
Promulgated by the FDA through the Code of Federal Regulations,
CGMP regulations establish the minimum practices necessary for a manufac-
turer to conform to the statutory requirement.12 The regulations outline gen-
eral rules for all aspects of [food and] drug manufacture, including buildings
and facilities, personnel, equipment, drug components and containers, produc-
tion, packaging and labeling, and record-keeping. 13 In the CGMP regulations,
FDA addresses, among other topics, equipment design, size and location; batch
production and control records; and personnel habits and responsibilities. In
one sense, the regulations are very specic, requiring personnel engaged in any
aspect of the manufacturing process to wear clean clothing appropriate for their
duties and practice good sanitation.14 On the other hand, the regulations do
not provide guidance as to what qualies as good sanitation and health habits.
Often the regulations will use the term adequate, without relating how the term
can be satised. For example, section 211.22(b) requires adequate laboratory
facilities for the testing and approval (or rejection) of components, drug product
containers, closures, packaging materials, in-process materials, and drug prod-
ucts... but there is no explanation indicating what features make a laboratory
adequate.15 Because the regulations are often very broad and vague, they allow
conicting, but plausible, views of the requirement; this, in turn, transform[s]
1221 C.F.R. 210.1(a) (1994); Barr Laboratories, 812 F.Supp. at 4<65.
13Barr Laboratories, 812 F.Supp. at 465.
1421 C.F.R. 211.28(a), (b) (1994).
1521 C.F.R. 211.22(b) (1994).
5what might be a routine evaluation into an arduous task.16 While oering sig-
nicantly more guidance than the statute, the CGMP regulations leave room
for subjective interpretation and allow arbitrary action by FDA inspectors.
In the Barr Laboratories decision, the court suggests that, when
the CGMP regulations create ambiguities, industry can obtain further guidance
from seminar and pharmaceutical rm literature, textbooks, reference books,
and FDA letters to manufacturers.17 Companies cannot use industry standards
alone to settle questions of CGMP compliance, however. According to the
Barr Laboratories court, industry standards themselves must be reasonable and
consistent with the spirit and intent of the CGMP regulations. 18 In addition to
these other sources, companies can rely upon FDA guidelines addressing CGMP
compliance.
FDA guidelines act as an advisory opinion directed generally to
the behavior of all those engaged in a certain type of activity and represent
the agency's best judgement standards.19 Unlike regulations, FDA guidelines
are not binding on industry; companies may follow the guidelines or they may
choose other, perhaps more innovative, methods.20 In addition, guidelines oer
greater exibility to FDA because FDA can provide advice to industry without
establishing an enforcement program.21 Guidelines can be adapted more quickly
than regulations and therefore can reect changing technology and business
16Barr Laboratories, 812 F.Supp. at 465.
17Barr Laboratories, 812 F.Supp. at 465.
181d.




In practice, guidelines do not oer the same exibility suggested in
theory. FDA inspectors are often suspicious of processes which dier from those
established in a guideline, giving the guideline the same binding eect as the
statute or regulations.23 FDA may also draft a guideline using language such
that following the recommendations in the guideline represents the only reliable
method for achieving compliance.24 In his article, Christopher Hagenbush uses
the example of FDA's draft process validation guidelines issued to interpret the
CGMP requirement for drugs.25 The draft guidelines establish the need for three
qualication runs on equipment, a suggestion which represents FDA's opinion
as to the number of repetitions necessary to establish tness of the equipment.
Hagenbush suggests a company would have a dicult time justifying fewer than
three qualication runs, especially since a court would probably defer to FDA's
judgment.26 Because the guidelines represent FDA's expert opinion, compa-
nies may have a dicult time substituting a dierent procedure for complying
with COMP requirements, even if the company's process is more procedure for
complying with CGMP requirements, even if the company's process is more
reasonable or more innovative. A company wishing to use a dierent proce-
dure must defend its requirement against the FDA guideline. Many companies





25Id. (citing 48 Fed. Reg. 13,096 (March 29. 1983)).
26ld.
7Process versus product regulation
As mentioned earlier, CGMP requirements focus regulatory eorts
on the manufacturing process rather than the nished product. CGMP require-
ments force FDA personnel, particularly the inspectors, to be familiar with
manufacturing technology and practices as well the specications with which
the nal product (food or drug) must comply. For instance, an FDA inspector
must know enough about manufacturing practices to determine if equipment has
the appropriate design and adequate size, as well as being suitably located.27 A
similar process-oriented requirement in the Clean Air Act{the mandatory inclu-
sion of the best available control technology (hereinafter, BACT) in the permit
for a major source or modication{shifts the attention of permit writers at the
Environmental Protection Agency (hereinafter, EPA) from emissions limits to
the technology for achieving those limits.28 The requirement that each permit
identify the best available control technology, to be employed at the permitted
facility, forces permit writers to become familiar with technologies used for pol-
lution control. In addition, permit writers must be able todetermine when a
technology does not qualify as BACT for a particular facility.29 Without these
272l C.F.R. 211.63 (1994).
28Each permit issued under the nondegradation program, also know as the Prevention
of Signicant Deterioration (PSD), must include emission limits, an analysis of air quality
impacts, and the imposition of BACT. Clean Air Act 165(a), 42 U.S.C. 7475(a). The Clean
Air Act denes BACT as an emission limitation based on the maximum degree of reduction
of each regulated pollutant that can be achieved considering the energy, environmental, and
economic impacts and other costs associated with the application of production processes or
available methods, systems and techniques. Clean Air Act  169(3), 42 U.S.C. 7479.
29BACT is determined on a case-by-case basis. In analyzing control technologies to deter-
mine BACT for a facility, the permit applicant must use a top-down approach which requires
the ranking of all available control devices in descending order of eectiveness. An applicant
must use the most stringent requirement as BACT, unless the applicant can prove, to the sat-
isfaction of the permitting authority, that technical considerations or energy, environmental,
or economic impacts make the use of the top-ranked technology infeasible. Once BACT is
established, the reviewing authority species an emissions limitation for the source that re-
8process-oriented requirements, regulators would focus solely on the output of the
facilities: FDA inspectors would determine the safety and ecacy of nished
foods and drugs, while EPA permit writers would concentrate on identifying ap-
propriate emissions limits. The manufacturers and the polluting facilities would
be responsible for determining the most eective methods for achieving the nal,
regulated product. Since the Federal Food, Drug, and Cosmetic Act and the
Clean Air Act already include these process-oriented regulations, the question
becomes: should the FDA and EPA be involved in regulating the process as
well as the product?
In both pollution control and the manufacture of food and drugs,
the outcome is strongly linked to the process, making government regulation of
the process as well as the product important. With BACT, the reviewing agency
establishes the emission limit for a facility based on the choice of a particular
control technology. Each control technology can achieve certain emission reduc-
tions, but each one also results in environmental, energy, and economic impacts.
The emission reduction capabilities are balanced against the possible impacts
in the selection of BACT. Because the reviewing authority sets the emission
limits for a facility based on the choice of a particular control technology, it is
important for the EPA to have the authority to be involved in the process of
pollution control{by mandating the use of a specic technology{as well as in
the regulation of the output.
ects the maximum degree of reduction achievable for each regulated pollutant. Oce of Air
Quality, Environmental Protection Agency, New Source Review Workshop Manual: Preven-
tion of Signicant Deterioration and Nonattainment Area Permitting (Draft) (October 1990)
(hereinafter, NSR Workshop Manual].
9Similar arguments can be made in defense of FDA authority to
establish CGMP for the manufacture of food and drug products. Good man-
ufacturing practices are particularly important when dealing with emerging
technologies and new products. For instance, with recombinant DNA and hy-
bridoma technology, there may be changes in potency or mutations during the
manufacturing process which can result in unintended and potentially danger-
ous alterations of the product.30 In such cases, it is necessary to regulate the
manufacturing practices in order to ensure the safety and ecacy of the n-
ished product. In addition, monitoring adherence to CGMPs can be important
in the manufacture of new products, which often involve new production oper-
ations, advanced technologies, and modied designs.31 Often, in the approval
of applications for new products, safety and ecacy decisions are based upon...
specications contained in the applications. Adherence to GMPs ensures that
these specications will be met consistently from one production run to another.
32 Because the quality of the product is often tied to the practices employed
in its manufacture, regulation of the process, as well as monitoring the nal
product, enables FDA to fulll its function of protecting public health by en-
suring the safety and ecacy of products. FDA regulation of manufacturing
practices also deters substandard operators who cut corners and gamble with
careless operations which pose serious hazards to public health.33
30Stuart L. Nightingale, Emerging Technologies and FDA Policy Formulation: The impact
of Government Regulation on Developing Drugs from New Technologies, 37 Food Drug Cosm.
L.J. 212, 220 (1982).
31Ronald M. Johnson, GMPs and the Product Review Process, 48 Food Drug Cosm. L.i.
299 (1993).
321d.
33Roscoe P. Kandle, Application of Current Good Manufacturing Practices, 24 Food Drug
10Despite the benets gained by linking regulation of the process and
product, there are some substantial drawbacks to having the EPA and FDA
involved in decisions aecting technology choices and manufacturing practices.
First, in order to properly evaluate control technologies and manufacturing prac-
tices, government personnel must be kept up-to-date with new developments and
innovations in the appropriate elds. This requires a signicant investment in
the training and education of EPA and FDA personnel, as well as drawing re-
sources and attention away from other agency functions. In addition, both the
BACT and the CGMP requirements may impact innovation by private indus-
try.34 Under the BACT requirement in the Clean Air Act, the permit species
the type of control technology to be used at a particular facility. The operator
must obtain a new permit if it wishes to make modications to the facility,
including the use of a dierent control technology. It may also be dicult to
have an innovative technology approved as BACT during the initial permit-
ting process. The operator ranks the available control technologies according
to their control eectiveness,35 and the top-ranked alternative must be selected
as BACT, unless the applicant can demonstrate signicant or unusual impacts
caused by the use of that technology at the facility. Therefore, if the innovative
technology is not ranked at the top of the list, it is unlikely that the technol-
ogy will be accepted as BACT. Private industry might be reluctant to invest in
the development of new control technologies due to the rigid selection process
Cosm. L.J. 9 (1969).
34But see Nightingale, supra note 30, at 220-221 (concluding that FDA regulation does not
impede innovation).
35N5R Workshop Manual, supra note 29, at B.22.
11and the lack of certainty that the technology could be employed by permitted
facilities.
The same uncertainties and limitations on exibility appear when
dealing with manufacturing processes regulated by the Federal Food, Drug, and
Cosmetic Act. The
CGMP regulations oer little incentive for innovation in manufac-
turing practices since not even prior approval of the selected standards and
practices through the NDA or ANDA guarantees compliance with CGMP. Fur-
thermore, as discussed above, the standards established in FDA regulations and
guidelines often become xed, forcing manufacturers to follow FDA's proce-
dures or justify their alternative practices. Although CGMPs are designed as
minimum standards, there is no guarantee that innovative practices will meet
or exceed these minimums; a manufacturer using an innovative procedure faces
the possibility of non-compliance with CGMP regulations. Since there are no
incentives for innovation, it is unlikely that manufacturers will take the initiative
and vary their practices from accepted CGMPs.
In order to counteract the inexibility currently associated with
CGMP regulations and guidelines, the FDA could focus on the general princi-
ples to be achieved through monitoring manufacturing practices, rather than on
the minor details which do not aect the quality ecacy or safety of a product.
36 A 1978 Federal Register notice discussed goal-oriented versus how to GMP
requirements. Goal-oriented GMPs would focus on what needs to be achieved
36Irwin S. Shupe. GMPs oAn Industry Point of Wew, 24 Food Drug Cosm. L.J. 14 (1969).
12and would provide exibility in how the requirement is met.37 Irwin Shupe,
writing as the Director of Quality Control at Winthrop Laboratories, echoed
similar sentiments. In his article, Mr. Shupe argues for emphasizing basic prin-
ciples of quality control rather than restrictive details; he suggests that specic
CGMP regulations can stie progress and lead to mediocrity.38 Less specic
CGMP regulations would encourage innovation and provide exibility for com-
panies in developing manufacturing practices. However, general regulations do
not provide sucient guidance in complying with CGMP requirements, and they
give greater discretion to FDA in enforcing the regulations. In addressing the
specicity of guidelines, both industry and FDA face a dilemma: general guide-
lines permit arbitrary action by FDA, while specic guidelines limit industry
exibility and stie innovation.
Conclusion
Process-oriented regulations present several drawbacks, including
restricting exibility and innovation by private industry. However, process-
oriented regulation serves as a valuable and important addition to product-
oriented regulation. By controlling the process, the agency has more condence
in the outcome. In addition, because of the impacts generated by the process, it
may be necessary for the relevant agencies to control the process as well as the
nished product. With the BACT regulations, EPA authority over the selection
of technology ensures that all environmental, energy, and economic impacts of
the choice are considered. Under the CGMP regulations, FDA can control the
37McNainara, supra note 4, at 660 (citing 43 Fed. Reg. 45,015 (1978)).
38Shupe, supra note?, at 16.
13manufacturing practices to ensure that the process results in safe and eective
products, t for human use. The best way to negotiate between the benets
of government control over the process and the desire for greater exibility and
innovation may be to allow greater involvement by industry in developing and
implementing process-oriented regulations.
14